Michael Gray
Institute of Biomedical Engineering
University of Oxford
Michael joined the BUBBL group in September 2015 primarily to work on a Phase-1 clinical trial of ultrasound-mediated targeted drug delivery for treatment of liver cancer. His current research efforts include a Phase-1 trial of ultrasound-triggered drug delivery to pancreatic tumours, clinical translation of quantitative cavitation monitoring techniques, and development of devices to enable the use of sound, magnetism, and light for targeted drug delivery.
Michael earned his doctorate from the Georgia Institute of Technology in 2015 after designing and demonstrating an ultrasonic system for deep tissue elastography. Over the preceding 23 years, Michael was a research engineer and principal investigator at Georgia Tech, working in research areas including submarine sonar, cetacean soft tissue characterization, photoacoustics, fish hearing, and non-destructive structural evaluation.
Is it safe to stop anticoagulants after successful surgery for atrial fibrillation?
Interactive cardiovascular and thoracic surgery Dec, 2011 | Pubmed ID: 21885540
In vivo ultrasonic attenuation in cetacean soft tissues.
The Journal of the Acoustical Society of America 02, 2017 | Pubmed ID: 28253670
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
The Lancet. Oncology 08, 2018 | Pubmed ID: 30001990
Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.
Radiology 04, 2019 | Pubmed ID: 30644817
Microbubbles, Nanodroplets and Gas-Stabilizing Solid Particles for Ultrasound-Mediated Extravasation of Unencapsulated Drugs: An Exposure Parameter Optimization Study.
Ultrasound in medicine & biology 04, 2019 | Pubmed ID: 30655109
Compensation of array lens effects for improved co-registration of passive acoustic mapping and B-mode images for cavitation monitoring.
The Journal of the Acoustical Society of America 07, 2019 | Pubmed ID: 31370617
Investigating the Role of Lipid Transfer in Microbubble-Mediated Drug Delivery.
Langmuir : the ACS journal of surfaces and colloids 10, 2019 | Pubmed ID: 31517490
Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
Theranostics , 2019 | Pubmed ID: 31534505
Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device.
Journal of controlled release : official journal of the Controlled Release Society 01, 2020 | Pubmed ID: 31733295
Indium-111 labelling of liposomal HEGF for radionuclide delivery via ultrasound-induced cavitation.
Journal of controlled release : official journal of the Controlled Release Society 03, 2020 | Pubmed ID: 31891732
Microbubbles Containing Lysolipid Enhance Ultrasound-Mediated Blood-Brain Barrier Breakdown In Vivo.
Advanced healthcare materials 02, 2021 | Pubmed ID: 33191662
Large-Volume Hyperthermia for Safe and Cost-Effective Targeted Drug Delivery Using a Clinical Ultrasound-Guided Focused Ultrasound Device.
Ultrasound in medicine & biology Apr, 2021 | Pubmed ID: 33451816
Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and Microbubbles.
Ultrasound in medicine & biology Mar, 2021 | Pubmed ID: 33707089
Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model.
International journal of radiation oncology, biology, physics Apr, 2021 | Pubmed ID: 33714528
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved